|
|
|
|
|
|
|
|
| Hello awha hawhwa, |
|
The financing round of GrOwnValve has just started, a MedTech startup that can fundamentally change the treatment of heart valve diseases.
Every year, around 1.4 million children are born with heart defects, and about every eighth person is affected during their lifetime. For those affected, this often means a lifelong burden and several follow-up surgeries. GrOwnValve addresses this massive, so far inadequately solved problem with a novel technology: growing, own-body heart valves, which are produced from the patient's own tissue directly in the operating room (Point-of-Care) and are implanted minimally invasively – without donor organs or external production.
GrOwnValve combines high medical relevance with a clearly differentiated technological approach that is patented several times and globally scalable. Initial clinical data underline the feasibility: In Germany, studies are underway with already completed procedures and good interim results. In India, three treated children have been living with these heart valves for over 9 years. GrOwnValve is supported by a strong network of medicine and research, including the Charité Berlin and the German Heart Center (DHZC), as well as funding programs such as the European Innovation Council (EIC). |
|
|
|
|
|
|
|
|
| INVESTMENT HIGHLIGHTS |
|
|
|
|
| • |
|
Life-changing for patients due to the regenerative, own-body heart valves |
|
|
| • |
|
1.4 million children are born with heart defects every year, approx. every 8th person is affected during their lifetime |
|
|
| • |
|
Multiple patented IP. Over 15 years of research & development |
|
|
| • |
|
Validation via EU funding and investments of EUR 8 million, more planned |
|
|
| • |
|
5 patients already successfully operated. |
|
|
| • |
|
Significant relief of the costs for health insurance companies and resources of the health system |
|
|
|
|
|
|
|
|
|
|
|
| What does GrOwnValve do? |
|
GrOwnValve is developing a process in which the patient's own tissue is processed directly during the operation into an individually adapted heart valve and implanted minimally invasively via catheter, without having to open the chest.
Since only the body's own material is used, the risk of rejection reactions and the need for long-term medication are eliminated. At the same time, the waiver of donor organs and external production enables a scalable and globally applicable system. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Companisto GmbH |
|
Köpenicker Str. 154, 10997 Berlin
Managing Director: Tamo Zwinge, LL. M. and David Rhotert
Amtsgericht: Berlin Charlottenburg HRB 132811 B
VAT-ID: DE 276 014 929
Phone: +49 30 330 837 49
Email: service@companisto.com |
|
|
|
|
|
|
|
|
| You receive this newsletter because you have subscribed to it. You can unsubscribe at any time via the unsubscribe link. |
|
| The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity. |
|
|
|
|
|
|
